Navigation Links
McMaster test detects the most prevalent respiratory viruses
Date:1/28/2008

Hamilton, ON (January 28) Diagnosing a nasty cough is now a lot easier thanks to a new test developed at McMaster University, which has just been approved by U.S. Food and Drug Administration (FDA) for use in the United States.

This new test simultaneously detects the most prevalent respiratory viruses, including flu and the common cold, helping doctors more accurately diagnose patients. It was developed by McMaster virologist Dr. James Mahony, in conjunction with Luminex Molecular Diagnostics (formerly TM Biosciences).

The xTAG Respiratory Viral Panel can detect most common respiratory viruses in a few hours. Traditional testing for this many viruses requires multiple individual diagnostic tests to be performed on a patient sample and can take several days to provide a thorough diagnosis. The speed and reliability of xTAG RVP will help physicians provide appropriate treatment, and prevent inappropriate antibiotic use that has contributed to the creation of "superbugs."

"Respiratory viruses affect millions of people each year and can lead to serious complications such as bacterial super infections and pneumonia. The RVP test allows healthcare providers to more rapidly and accurately detect infected patients and take appropriate measures to treat and reduce the spread of the disease," said Mahony, who is the director of the McMaster University Regional Virology and Chlamydiology Laboratory at St. Joseph's Healthcare Hamilton and is a professor in the Department of Pathology and Molecular Medicine at McMaster.

The FDA approval allows U.S. laboratories to use the test to simultaneously detect and identify 12 viruses and viral subtypes that together are responsible for more than 85 percent of respiratory viral infections, including influenza A, influenza A-H1, influenza A-H3, influenza B, Adenovirus, respiratory syncytial virus (RSV) A and B, metapneumovirus, parainfluenza 1, 2, and 3, and rhinovirus.

The test is also CE ("Conformit Europenne") certified to detect and identify 20 viruses and viral subtypes in Europe, adding eight viruses and subtypes including SARS and influenza A H5 (the subtype associated with avian influenza). Luminex is currently working to get the panel certified for patient use in Canada, although it is already available for investigational use.

Development of the xTAG Respiratory Viral Panel began in May 2005, when the company signed an agreement with McMaster to collaborate on the development of the test panel. After the prototype was created and validated at McMaster in Mahonys lab based t St. Josephs Healthcare, the panel was further developed and commercially launched by Luminex.

Its rewarding to see a McMaster technology enter the marketplace in a way that will directly improve the treatment of patients, Elsie Quaite-Randall, executive director of the McMaster Industry Liaison Office (MILO). This is a great example of a win-win collaboration that transformed great research into a product that benefits patients.


'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Related medicine news :

1. CT colonography detects wide-range of extracolonic abnormalities in elderly patients
2. Blood protein detects lung cancer, even at earliest stage
3. New technique detects specific chromosomal damage, may indicate lung cancer risk
4. Preschoolers nightmares less prevalent, are trait-like and associated with personality
5. BRCA1 Mutation Prevalent Among Hispanic, Younger Black Women
6. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
7. Prominent Respiratory Therapist and Author Joins StopSmokingConnection.com as a COPD Expert
8. Reckitt Benckiser Commences Cash Tender Offer for All Outstanding Shares of Adams Respiratory Therapeutics
9. Nationwide Respiratory Signs Preferred Pulse Oximetry Agreement with Masimo
10. Kids Respiratory Virus Season Off and Running
11. New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer of ... was more than humbled by customer demand over the Mother’s Day Weekend promotion. So ... Now that Bunion Bootie has completely replenished its inventory levels, it hopes to continue ...
(Date:5/26/2016)... ... 2016 , ... The introduction of our professional athletes coincides with the company’s ... , “We are proud to introduce Meghan Klingenberg, defender and World Champion with ... wide receiver for Los Angeles who was a second round selection in the 2012 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film ... FCPX. , "This new layered style transition tool will keep a consistent flow to ... of Pixel Film Studios. , TranSweep is an all new layered style transition ...
(Date:5/26/2016)... ... 26, 2016 , ... According to the Webster’s dictionary, a hippie is defined ... products, one company is going against the norm with a line of all-natural skincare ... in the green space is proud to announce its latest retail partnership with the ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
Breaking Medicine Technology: